Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6190]

ASCO 2019: Adding enzalutamide to standard first-line treatment improves survival for men with metastatic hormone-sensitive prostate cancer

ASCO 2019: Adding enzalutamide to standard first-line treatment improves survival for men with metastatic hormone...

ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

ASCO 2019: Drug targeting DNA damage response shows promise against cancers of anus and genitals

ASCO 2019: Drug targeting DNA damage response shows promise against cancers of anus and genitals

ASCO 2019: Front-line pembrolizumab is promising alternative to chemotherapy for advanced gastroesophageal junction and gastric cancers

ASCO 2019: Front-line pembrolizumab is promising alternative to chemotherapy for advanced gastroesophageal...

ASCO 2019: Adding ribociclib to first-line endocrine therapy significantly improves survival for pre-menopausal women with advanced breast cancer

ASCO 2019: Adding ribociclib to first-line endocrine therapy significantly improves survival for pre-menopausal...

ASCO 2019: Pembrolizumab increases historic survival rate for certain people with advanced non-small cell lung cancer

ASCO 2019: Pembrolizumab increases historic survival rate for certain people with advanced non-small cell lung...

FDA approves lenalidomide for follicular and marginal zone lymphoma

FDA approves lenalidomide for follicular and marginal zone lymphoma

Interaction with stromal cells influences tumour growth and metastasis in pancreatic cancer

Interaction with stromal cells influences tumour growth and metastasis in pancreatic cancer

Cancer-fighting combination targets glioblastoma

Cancer-fighting combination targets glioblastoma

ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

More from ecancer